Literature DB >> 11704849

The theory of APL.

F Piazza1, C Gurrieri, P P Pandolfi.   

Abstract

Acute promyelocytic leukemia (APL) is associated with reciprocal and balanced chromosomal translocations always involving the Retinoic Acid Receptor alpha (RARalpha) gene on chromosome 17 and variable partner genes (X genes) on distinct chromosomes. RARalpha fuses to the PML gene in the vast majority of APL cases, and in a few cases to the PLZF, NPM, NuMA and STAT5b genes. As a consequence, X-RARalpha and RARalpha-X fusion genes are generated encoding aberrant fusion proteins that can interfere with X and/or RARalpha function. Here we will review the relevant conclusions and the open questions that stem from a decade of in vivo analysis of APL pathogenesis in the mouse in transgenic and knock-out models.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11704849     DOI: 10.1038/sj.onc.1204855

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

Review 1.  Molecular rearrangements and morphology in thyroid cancer.

Authors:  Todd G Kroll
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

2.  Dimerization-induced corepressor binding and relaxed DNA-binding specificity are critical for PML/RARA-induced immortalization.

Authors:  Jun Zhou; Laurent Pérès; Nicole Honoré; Rihab Nasr; Jun Zhu; Hugues de Thé
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-06       Impact factor: 11.205

3.  PML-retinoic acid receptor alpha inhibits PML IV enhancement of PU.1-induced C/EBPepsilon expression in myeloid differentiation.

Authors:  Hitoshi Yoshida; Hitoshi Ichikawa; Yusuke Tagata; Takuo Katsumoto; Kazunori Ohnishi; Yukihiro Akao; Tomoki Naoe; Pier Paolo Pandolfi; Issay Kitabayashi
Journal:  Mol Cell Biol       Date:  2007-06-11       Impact factor: 4.272

4.  MOZ increases p53 acetylation and premature senescence through its complex formation with PML.

Authors:  Susumu Rokudai; Oleg Laptenko; Suzzette M Arnal; Yoichi Taya; Issay Kitabayashi; Carol Prives
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

Review 5.  [Risk-adapted therapy of acute myeloid leukemia].

Authors:  W Hiddemann; K Spiekermann; J Braess; M Feuring-Buske; C Buske; T Büchner
Journal:  Internist (Berl)       Date:  2006-06       Impact factor: 0.743

6.  A high-content screening (HCS) assay for the identification of chemical inducers of PML oncogenic domains (PODs).

Authors:  Kenneth W Yip; Michael Cuddy; Clemencia Pinilla; Marc Giulanotti; Susanne Heynen-Genel; Shu-ichi Matsuzawa; John C Reed
Journal:  J Biomol Screen       Date:  2011-01-13

Review 7.  The APL paradigm and the "co-clinical trial" project.

Authors:  Caterina Nardella; Andrea Lunardi; Akash Patnaik; Lewis C Cantley; Pier Paolo Pandolfi
Journal:  Cancer Discov       Date:  2011-07       Impact factor: 39.397

Review 8.  How animal models of leukaemias have already benefited patients.

Authors:  Julien Ablain; Rihab Nasr; Jun Zhu; Ali Bazarbachi; Valérie Lallemand-Breittenbach; Hugues de Thé
Journal:  Mol Oncol       Date:  2013-02-11       Impact factor: 6.603

9.  Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL.

Authors:  Nicole Clarke; Ana M Jimenez-Lara; Emilie Voltz; Hinrich Gronemeyer
Journal:  EMBO J       Date:  2004-07-08       Impact factor: 11.598

Review 10.  Designed transcription factors as structural, functional and therapeutic probes of chromatin in vivo. Fourth in review series on chromatin dynamics.

Authors:  Fyodor D Urnov; Edward J Rebar; Andreas Reik; Pier Paolo Pandolfi
Journal:  EMBO Rep       Date:  2002-07       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.